Acquisition by John Young of 1017 shares of Exelon subject to Rule 16b-3
| PFE Stock | 25.22 0.37 1.49% |
Slightly above 52% of Pfizer's private investors are presently thinking to get in. The analysis of current outlook of investing in Pfizer Inc suggests that some traders are interested regarding Pfizer's prospects. Pfizer's investing sentiment can be driven by a variety of factors including economic data, Pfizer's earnings reports, geopolitical events, and overall market trends.
Pfizer |
Filed transaction by Exelon Corp director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Pfizer Fundamental Analysis
We analyze Pfizer's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Pfizer is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Pfizer Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pfizer stock to make a market-neutral strategy. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics with similar companies.
Peers
Pfizer Related Equities
| LLY | Eli Lilly | 4.58 | ||||
| AMG | Amgen | 2.87 | ||||
| GIS | General Mills | 1.44 | ||||
| BAYN | Bayer AG | 0.37 | ||||
| ZEG | AstraZeneca PLC | 0.04 | ||||
| JNJ | Johnson Johnson | 0.13 | ||||
| IDP | Biogen | 0.67 |
Additional Tools for Pfizer Stock Analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.